The answer so far
The knee-pain report describes one clinic’s patients, not an 11-in-12 chance that BPC-157 will work for another person.
A small 2021 report said 11 of 12 contacted patients who received BPC-157 alone reported less knee pain. It had no placebo or untreated group, relied on recall and did not show that cartilage or ligaments repaired. The result is a reason for further research, not a reliable prediction for an individual.16
On this page
Where does “11 out of 12” come from?
A 2021 report reviewed patients treated for knee pain at one US clinic. Seventeen people had received treatment; 16 were reached by telephone. Of those contacted, 12 had received BPC-157 alone, and the authors reported improvement in 11 and no improvement in one. That is a report of patients’ experiences, not an 11-in-12 chance that the peptide will work for someone else. The patients paid for the treatment.1
What about the other four people?
The other four people contacted received BPC-157 and a second peptide the paper calls thymosin beta-4, or TB4. Three reported improvement and one did not. This was not a randomised comparison between the two groups, and the paper’s TB4 is not automatically the same as a product sold as TB-500. Neither group tells us what a seller-defined blend will do. Understand thymosin beta-4 and TB-500.17
- 17 treatedThe clinic reviewed records; one person could not be reached for the phone follow-up.
- 12 received BPC-157 aloneOf the people contacted, 11 reported improvement and one did not.
- 4 received two peptidesThe paper calls the second peptide thymosin beta-4; three reported improvement.
- No comparison groupThere was no untreated or placebo group and no follow-up imaging showing tissue repair.
What did the study actually measure?
Patients were asked by telephone to recall their pain before and after treatment, how long any relief lasted, and aspects of mobility, exercise and sleep. Follow-up times varied. Their experiences matter, but there was no untreated or placebo group and no objective testing to verify changes in function. The study cannot separate a peptide effect from changes over time, other care, expectations or recall.1
Why does a comparison group matter?
Pain can change for many reasons, and improvement after a treatment does not by itself establish what caused it. For example, a separate randomised study of 251 people over age 59 with knee osteoarthritis compared injections of hyaluronate—a substance used in some joint treatments—with saline; pain and function improved over time in all groups, without a significant difference between them. That study did not test BPC-157 and does not tell us what its effect is. It illustrates why a suitable comparison matters.2
Did it show cartilage or a torn ligament regrew?
No. Four of the 16 contacted patients had MRI scans before treatment, showing different findings; the report did not present follow-up scans demonstrating tissue repair. Its authors discussed possible cartilage repair and fewer operations, but those outcomes were not established by this study. Less pain, better function and a healed structure are related questions, not interchangeable measurements. Follow the separate tendon evidence.
For the separate joint question, see what the AOD-9604 cartilage study actually showed.1
Did it show BPC-157 is better than a steroid?
The report discusses steroid injections, but it did not randomly compare BPC-157 with a steroid treatment. It cannot establish which would relieve pain more, work longer or have fewer harms. The small size and telephone follow-up also cannot establish long-term safety or identify uncommon adverse events. The human-evidence guide explains the wider research.16
What if I have knee pain now?
Knee pain has different causes, and the appropriate assessment depends on symptoms and circumstances. Seek urgent medical assessment if you cannot bear weight or move the knee, or if a hot, swollen knee occurs with fever or feeling unwell; infection is one possible cause. A clinician or physiotherapist can help identify the problem and discuss suitable care. Explore the joint and recovery guide, or return to the BPC-157 overview. For the difference between tissues, see tendon, ligament and muscle injuries.345
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee and Padgett / Alternative Therapies in Health and Medicine · Published retrospective uncontrolled case series; full report inspected
- Intra-articular sodium hyaluronate versus physiological saline for painful knee osteoarthritis: a randomised clinical trialScandinavian Journal of Rheumatology / PubMed · 2008 primary randomised trial
- Knee painNHS · UK public-health guidance
- Septic arthritisNHS · UK public-health guidance
- Osteoarthritis: diagnosis, treatment and steps to takeU.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases · US public-health guidance
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safetyPeer-reviewed systematic review / PubMed · Systematic review; very low certainty evidence
- FDA briefing on TB-500-related bulk drug substancesU.S. Food and Drug Administration · Advisory committee briefing; United States; July 2026